Navigation Links
Fluid theory confirmed by Foton
Date:9/25/2007

lla Materia), University of Milan, Italy.

To the delight of the science team, the images visually support the theoretical predictions by showing a very large increase in the size of the fluctuations. Data analysis has also shown that the amplitude of the fluctuations in temperature and concentration greatly increased.

It is a rare event when a space mission is able to confirm a theoretical prediction in such record time, said Olivier Minster, Head of ESAs Physical Sciences Unit. These results are important because they are the first verification of the effects forecast a decade ago.

The availability of these images from the spacecraft has enabled us to change what we are doing so that we can optimise the scientific return from the mission, said Professor David Cannell of the University of California at Santa Barbara (UCSB). We will also have many thousands of images to analyse back in our labs after the experiment returns to Earth. This will keep us busy for quite a while.

It may be that our results will influence other types of microgravity research, such as the growth of crystals. Our research may even lead to some new technological spin-offs, said Professor Giglio.

GRADFLEX is one of 43 ESA scientific and technological experiments on board the 12-day Foton-M3 mission. The mission is scheduled to end on 26 September, when the re-entry capsule will return to Earth in Kazakhstan. The onboard experiments will be returned to their home institutions where the data will be carefully analysed over the coming months.


'/>"/>

Contact: Olivier Minster
Olivier.Minster@esa.int
31-715-654-764
European Space Agency
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Microfluidic analysis of multiplex PCR products for the genotyping of Helicobacter pylori
2. Maximize Viral RNA Yield from Biological Fluid
3. Genomic DNA Isolation From 1 ml of Body Fluid
4. Total RNA Isolation From 500 l Body Fluid
5. Simultaneous Screening of 23 Drugs of Abuse in Oral Fluid Using an LC/MS/MS Method
6. XANTHOCHROMIA IN CEREBROSPINAL FLUID
7. Gram Quantities of MAb Produced with Simple Bioreactor in Serum-Free Perfusion Culture Replacing Ascitic Fluid Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015 LabStyle Innovations Corp. (OTCQB: ... today announced it recently closed a round of ... used to support the global rollout and initial ... cloud-based, diabetes management solution that includes novel software ... glucose monitoring device, and for working capital purposes. ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for excessive ... commercially available new FDA approved system in the last 14 years, and the only ... Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, and ...
(Date:8/28/2015)... August 28, 2015 According to ... Sera, Cryogenic Storage Systems, Thawing Equipment, Alarms), by Biospecimen ... Clinical Trials), End User - Global Forecast to 2020", ... to reach USD 3,731.03 Million by 2020 from USD ... 11.65% between 2015 and 2020. Browse ...
(Date:8/28/2015)... ... 2015 , ... Riordan-McKenna Institute founders, stem cell ... the use of sterile, dehydrated amniotic tissue AlphaPATCH™ developed by Amniotic Therapies ... knee wound. , The case involved a 78-year-old male, who presented with a ...
Breaking Biology Technology:LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4
... of Integrated Global Services, CAMBRIDGE, Mass., April ... under a new name, Abt Bio-Pharma Solutions, Inc., ... company will continue to,provide custom strategic, research and ... diagnostics industries,utilizing a team approach that blends decades ...
... 1, 2008 Cardium Therapeutics,(Amex: CXM ... announced today that,InnerCool has entered into a ... a leading distributor of cardiology,medical products. Under ... have,exclusive marketing, sales and distribution rights in ...
... N.J., April 1, 2008 Derma Sciences,Inc (OTC Bulletin ... that sales for 2007 were $34.1 million, an increase ... Gross margins held steady at 34,percent, but due primarily ... the,pipeline, and expanding the Company,s marketing and sales staffs, ...
Cached Biology Technology:Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc. 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 3Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 5Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 6Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 7Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 8Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 9Derma Sciences Reports Fourth Quarter Year-End Results for 2007 2Derma Sciences Reports Fourth Quarter Year-End Results for 2007 3Derma Sciences Reports Fourth Quarter Year-End Results for 2007 4Derma Sciences Reports Fourth Quarter Year-End Results for 2007 5
(Date:8/25/2015)... and BELLEVUE, Wash. , Aug. ... advanced robotic systems, announced today it will unveil its ... vehicle (UGV), at the National Tactical Officers Association Conference ... The Guardian S is the first-ever commercially available ... years of research and in-field trials and is protected ...
(Date:8/20/2015)... Calif. , Aug. 20, 2015 ... on consumers that are active and healthy. However, ... in the hospital environment to help improve diagnostic ... a video from the Wearable Technologies Conference ... discussed new applications for wearables in healthcare.    ...
(Date:8/19/2015)... Aug. 19, 2015  VOXX International Corporation (Nasdaq: ... entered into a Definitive Agreement to purchase the ... authentication market leader EyeLock through an acquiring entity.  ... a controlling interest in the acquiring entity. The ... of due diligence.  Expanding on its existing supply ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... HORSHAM, PA (January 11, 2008): Nucleonics, Inc., ... development of novel RNA interference (RNAi)-based therapeutics, announced ... in a Phase 1 human safety study of ... (HBV) infection, NUC B1000. NUC B1000 ...
... a tiny sensor that could be used to detect ... and chemical warfare agents, much more quickly than current ... of gas chromatography and mass spectrometry and shrunk them ... computer mouse. Eventually, the team, led by MIT Professor ...
... The Stowers Institutes Xie Lab has published findings that ... cells within their cellular microenvironment, called a niche. ... Cell Stem Cell. The Xie Lab demonstrated that ... human cancer stem cells, can out-compete normal stem cells ...
Cached Biology News:Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic 2Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic 3MIT gas sensor is tiny, quick 2
...
...
...
D.R. Harper and C. Grose (1994) • Includes: virus structure & replication, fundamental virology, immunology and pathogenesis, vaccines and antiviral drugs, novel diagnostic techniques, cloning a...
Biology Products: